Abstract 484P
Background
In South Korea, tx for patients (pts) with stage I–IIIA NSCLC is resection, ± systemic tx for stage II and select stage III disease. Osimertinib is a 3rd-generation EGFR-TKI approved as adjuvant tx for resected stage IB–IIIA EGFRm NSCLC, based on ADAURA trial results. To understand rw data prior to adjuvant osimertinib approval, we report EGFR mutation types, tx patterns / outcomes from the South Korean cohort of a global retrospective rw study.
Methods
Medical records of eligible pts (≥18 years [yrs] with resected stage IA–IIIA NSCLC and a positive EGFRm test result, diagnosed between 01 Jan 2014–31 Dec 2017), were assessed from diagnosis (Dx) until last follow-up/death or 31 Dec 2020. Primary objectives included: EGFR mutation type and frequency, tx patterns and overall survival (OS). Site of first recurrence was a secondary objective.
Results
Of 200 pts in South Korea with EGFRm NSCLC, 95 (48%) had Ex19del and 87 (44%) L858R. At Dx, median age was 62 yrs (range: 36–83), 133 pts (67%) were female, 145 (73%) were never smokers; 68 pts (34%) had stage IA disease, 43 (22%) IB, 20 (10%) IIA, 15 (8%) IIB, and 54 (27%) IIIA. In total, 90 pts (45%) received surgery only; 74 (37%) had surgery + adjuvant tx only; 22 (11%) had neoadjuvant + surgery + adjuvant tx; 14 (7%) had salvage/post-recurrence tx (see Table). After median follow-up of 54.7 months from Dx (IQR 44.5–70.1), 5-yr OS was 69% (96% in stage IA, 84% IB, 72% IIA, 73% IIB, 26% IIIA). Of 106 pts who received systemic tx with first recurrence data available, 53 had metastatic recurrence, most commonly in the lung (19/53; 36%) and brain (18/53; 34%).
Conclusions
In this rw study of pts in South Korea with resected EGFRm early-stage NSCLC (Dx 2014–2017), 45% of pts received surgery only and <50% received surgery + adjuvant/neoadjuvant tx; 5-yr OS was suboptimal at 69%. Early Dx and EGFR mutation testing are needed to ensure eligible pts have access to suitable adjuvant tx to improve clinical outcomes. Table: 484P
Treatment received, n (%) | Patients in South Korea (N=200) |
Proportion of patients with surgery only | 90 (45) |
Proportion of patients with neoadjuvant and surgery and adjuvant (within 26 weeks of surgery) treatment* | 22 (11) |
Proportion of patients with surgery and adjuvant (within 26 weeks of surgery) treatment only | 74 (37) |
- Chemotherapy | 73 (99) |
- Targeted therapy | 1 (1) |
- Immunotherapy | 0 |
Proportion of patients with surgery and treatment >26 weeks after surgery (post-recurrence/salvage) | 14 (7) |
- Chemotherapy | 1 (7) |
- Targeted therapy | 14 (100) |
- Immunotherapy | 0 |
Percentages may equal to >100% as patients could have received >1 type of systemic treatment. *No patients received neoadjuvant treatment only.
Clinical trial identification
Editorial acknowledgement
The authors would like to acknowledge Rachel Gater, PhD, of Ashfield MedComms, an Inizio Company, for medical writing support that was funded by AstraZeneca in accordance with Good Publications Practice (GPP) guidelines (https://www.ismpp.org/gpp-2022).
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
M. Ahn: Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Advisory Board, Honoraria: Bristol Myers Squibb, Merck Sharp & Dohme, Ono Pharmaceutical Co., Ltd., Roche; Financial Interests, Personal, Speaker, Consultant, Advisor: Alpha Pharmaceutical, AstraZeneca, Bristol Myers Squibb, Merck Sharpe & Dohme, Ono Pharmaceutical Co. Ltd., Roche, Takeda. J.H. Kang: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Boehringer Ingelheim, AstraZeneca, Novartis, Yuhan Corporation, Ono PHARMA, Genexine; Non-Financial Interests, Personal, Research Funding: Daiichi Sankyo, Boehringer Ingelheim; Non-Financial Interests, Personal, Speaker’s Bureau: MSD, AstraZeneca, Roche, Takeda, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Bristol Myers Squibb, Yuhan Corporation, Bayer. S. Kim: Financial Interests, Personal, Advisory Role, Advisory meeting participation: AstraZeneca; Financial Interests, Personal, Advisory Board, Advisory meeting participation: Amgen, Boehringer Ingelheim, Janssen, Novartis, Takeda, Therapex, Yuhan; Financial Interests, Personal, Other, Lecture: Boehringer Ingelheim; Financial Interests, Personal, Research Funding: Yuhan. D. Kahangire: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. S.P. Nagar, K.L. Davis, M. Jimenez: Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor, RTI Solutions received consulting fees: AstraZeneca. M. Jung: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. M. Sandelin: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks or ownership: AstraZeneca. B.C. Cho: Financial Interests, Personal, Advisory Board: KANAPH Therapeutic Inc, Bridgebio therapeutics, Cyrus therapeutics, Guardant Health, Oscotec Inc; Financial Interests, Personal, Advisory Role, Consulting fees: Abion, BeiGene, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc., Janssen, Takeda, MSD, Janssen, Medp; Financial Interests, Personal, Member of Board of Directors: Interpark Bio Convergence Corp., J INTS BIO; Financial Interests, Personal, Other, Founder: DAAN Biotherapeutics; Financial Interests, Personal, Research Grant: MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, AbbVie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Onoclogy, CJ bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Jans; Financial Interests, Personal, Royalties: Champions Oncology, Crown Bioscience, Imagen; Financial Interests, Personal, Stocks/Shares: TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., J INTS BIO. All other authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract